<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311086</url>
  </required_header>
  <id_info>
    <org_study_id>SPYRAL DYSTAL</org_study_id>
    <nct_id>NCT04311086</nct_id>
  </id_info>
  <brief_title>SPYRAL DYSTAL Clinical Study</brief_title>
  <official_title>Global Clinical Study of Renal Denervation in the Distal Main and First Order Branch Renal Arteries Using the Symplicity Spyral™ Multi-electrode Renal Denervation System (SPYRAL DYSTAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this single arm interventional study is to determine if renal denervation
      performed in the distal main and first order branch renal arteries is as effective in
      reducing blood pressure as the procedural approach used in the SPYRAL HTN-OFF MED clinical
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic blood pressure (SBP) from baseline as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>From baseline to 3 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure (SBP) from baseline as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office systolic blood pressure</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office diastolic blood pressure</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office diastolic blood pressure baseline as measured by 24-hour ABPM</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of achieving target office BP</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of BP reduction pattern over 24 hours of ABPM</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural characteristics (e.g. Procedure time, contrast media usage, etc.)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic safety by evaluating incidence of Major Adverse Events</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myocardial Infarction</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stroke</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Renal artery re-intervention</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major bleeding according to TIMI definition</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Increase in serum creatinine &gt;50%</measure>
    <time_frame>From baseline to 12 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypertension</condition>
  <condition>Vascular Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation (Symplicity Spyral™)</intervention_name>
    <description>Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.</description>
    <arm_group_label>Renal Denervation</arm_group_label>
    <other_name>Renal Angiography</other_name>
    <other_name>Renal Denervation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Individual has office systolic blood pressure (SBP) ≥ 150 mmHg and &lt;180 mmHg and a
        diastolic blood pressure (DBP) ≥ 90 mmHg after being off medications.

          -  Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP ≥ 140
             mmHg and &lt; 170 mmHg.

          -  Individual is willing to discontinue current antihypertensive medications

        Exclusion Criteria:

          -  Individual has estimated glomerular filtration rate (eGFR) of &lt;45.

          -  Individual has type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus.

          -  Individual has one or more episodes of orthostatic hypotension.

          -  Individual requires chronic oxygen support or mechanical ventilation other than
             nocturnal respiratory support for sleep apnea.

          -  Individual has primary pulmonary hypertension.

          -  Individual is pregnant, nursing or planning to become pregnant.

          -  Individual has frequent intermittent or chronic pain that results in treatment with
             nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the
             month prior to enrollment.

          -  Individual has stable or unstable angina within 3 months of enrollment, myocardial
             infarction within 3 months of enrollment; heart failure, cerebrovascular accident or
             transient ischemic attack, or atrial fibrillation at any time.

          -  Individual works night shifts.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Sharp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Wales</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M Wanten</last_name>
    <phone>+17075250111</phone>
    <email>rs.spyraldystal@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David P Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kandzari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Choi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland Schmieder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Mahfoud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philipp Lurz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Konstantinos Tsioufis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Verona Borgo Trento</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flavio Ribichini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joost Daemen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Sharp, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Renal denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

